Table of Content - Volume 12 Issue 3 - December 2019
Ravikeerthi G1, Vibha B2*
1Assistant Professor, 2Postgraduate, Department of ENT-H and N, Sapthagiri Institute of Medical Sciences and Research Centre, No.15, Chikkasandra, Hesarghatta main road, Bangalore-560090, INDIA.
Abstract Aims and Objectives: To assess demographic factors involved in outcome in patients receiving intratympanic injection for ISSNHL To determine effect of co-morbidity like Diabetes mellitus and Hypertension on the outcome of patient receiving intratympanic injection. To assess improvement after 3rd dose and 6th dose intratympanic injection by audiological evaluation using pure tone audiometry. Key Word: intratympanic dexamethasone.
INTRODUCTION Sudden hearing loss (SHL) was first described by de Kleyn in 1944 and defined as a hearing loss of at least 30 dB in three sequential frequencies in the standard pure tone audiogram over three days or less. It may be characterized as an impairment of the inner ear and/or central auditory pathways, with variable intensity and frequency, ranging from mild feeling of ear being clogged to total loss of hearing. Although it is thought to originate mainly from viral, vascular, or immunologic causes, the etiopathogenesis of the disease is still unknown, so the disease is usually referred to as idiopathic sudden hearing loss (ISHL). It has a reported incidence of 5---20 per 100,000 patients per year, with a mean of 50-60 years and no predominance of sex. In most cases, there is unilateral hearing loss, with bilateral involvement reported in less than 5%. Recovery rate in untreated patients ranges from 25% to 50%, mostly resolving within two weeks of onset of symptoms. Although the methods of treatment of SHL patients vary among different centers, systemic steroid (SS) therapy is the most commonly used modality for treatment of sudden hearing loss. The treatment of sudden hearing loss is based on its etiology. In idiopathic cases, oral corticosteroids are widely used; intratympanic steroids have been trialed in patients with sudden hearing loss, because they provide a high concentration in the labyrinth in animal models, although their results are conflicting. Intratympanic steroid has become an attractive alternative, especially in cases when systemic therapy fails, or to avoid the side effects of the systemic use of steroids. However, the standardization of number and frequency of intratympanic treatments and drug delivery methods remain to be determined. Many treatments for ISSHL have been tested and found ineffective. These include hyperbaric oxygen, agents that decrease blood viscosity (osmotic diuretics, pentoxifylline, procaine, and heparin), vasodilator drugs (histamine, papaverine, verapamil, and carbogen), free radical scavenging vitamins, gingko biloba, and magnesium. At this time, the only treatment for ISSHL shown effective in controlled clinical trials is systemic corticosteroid therapy with high dose of prednisone taper. The reported success rate is around 50 to 80%, whereas the spontaneous recovery rate is approximately 30 to 60%. Despite high reported spontaneous recovery rates, the practical experience of many otologists suggest that, hearing recovery is poor in those patients who have failed systemic intravenous therapy Advantages
Disadvantages/ Complications
Grading Of Severity Of Hearing Loss
MATERIALS AND METHODS A retrospective study from October 2017 to October 2019, was conducted in Sapthagiri Institute of Medical Sciences an Research Centre, Benagluru. 35 patients who were diagnosed with sudden unilateral SSNHL received intratympanic dexamethasone injection under endoscopic examination of affected ear. Six injection protocols were employed: injection of 2 ml dexamethasone(5 mg/ml)three times a week (alternate day regimen) for a total of 6 doses. Oral steroid dexamethasone 8mg twice daily for 1 week and dose was gradually tapered. Multi vitamin tablets were also given orally. Hearing recovery was assessed by pure tone audiogram done after 3rd injection and 6th injection. Ethical clearance was obtained from the institute’s ethical clearance committee. Informed consent was taken from the cases after explaining the procedure. Procedure: The patient is positioned in the supine position. With a 26 gauge 1 &1/2 inch long needle and Tuberculin syringe, a puncture was made in the posterosuperior quadrant .2 ml of dexamethasone injection (5mg/ml) was injected through this site. Patient should avoid the swallowing reflex and patient should remain in the same position with head tilted 45 degrees to the opposite side for 15 to 20 minutes Inclusion Criteria
Exclusion criteria
RESULTS Out of 33 cases that were taken for study,
Figure1: Graph depicting age preponderance; Figure 2: Graph depicting the affected ear; Figure 3: Graph depicting sex preponderance Table 1: Table showing incidence of co-morbidities associated with ISSNHL
Figure 4: Graph depicting audiological improvement after 3rd dose and 6th dose of intratympanic injection. In 6th PTA, out of 15 who had improvement of 10-20dB, 11 were female and 4 were male. CONCLUSION Sudden SNHL is an otologic emergency. If treated at correct time, it can be potentially reversed. Currently, steroids are the most potent medication used in treating sudden SNHL. The main purpose of using steroids in sudden SNHL is activation of all the glucocorticoid receptors in the cochlea. By definition, ISSNHL is from an unknown etiology and is a result of multiple unknown causes. Within this heterogeneous group, there are likely to be early, late, and non-responders to steroid treatment. There may also be a number of patients who are recovering spontaneously, regardless of steroid therapy. This has been reported to be somewhere between 31% and 65%. In our study we can conclude that female preponderance is more than males and most commonly affected in the 4th decade. left ear is more affected than right ear. Presence of co-morbidities like diabetes and hypertension hinder the effect of intratympanic injection. Majority of the patients showed significant improvement of 10-20dB after 6th dose.
REFERENCES
|
|